Urolithin A vs NMN

Both target mitochondrial ageing from different angles: urolithin A promotes removal of damaged mitochondria, while NMN replenishes NAD+, a coenzyme mitochondria need.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Urolithin A

A gut-microbiome metabolite of ellagitannins (pomegranate, berries, nuts) that stimulates mitophagy — the recycling of damaged mitochondria.

BEST STUDIED FOR

Mitochondrial & longevity

Read the cited profile →

🧪

NMN

A direct precursor of NAD+, studied in human trials as a way to raise NAD+ levels that decline with age.

BEST STUDIED FOR

Mitochondrial & longevity

Read the cited profile →

SIDE BY SIDE

	Urolithin A	NMN
The key difference	Mitophagy inducer	NAD+ precursor
Class	Mitochondrial & longevity	Mitochondrial & longevity
Mechanism	Only some people’s gut bacteria convert dietary ellagitannins to urolithin A.	NMN is converted to NAD+ by NMNAT enzymes; NAD+ is a cofactor for energy metabolism and for sirtuins and PARPs.
Status	Several randomised human trials in middle-aged and older adults and athletes; marketed as a supplement.	Multiple small randomised human trials (insulin sensitivity, walking speed, aerobic capacity, sleep). Regulatory status of NMN as a supplement varies by country.
Reported safety signals	Trials report it as well tolerated over the study periods.	Trials and reviews report it as well tolerated over weeks to months; long-term human data are still limited.
A key study	A randomised placebo-controlled trial measured muscle strength and mitochondrial biomarkers with urolithin A in middle-aged adults. (Cell Rep Med 2022, PMID 35584623)	A randomised trial in prediabetic women measured muscle insulin sensitivity after NMN supplementation. (Science 2021, PMID 33888596)

WHEN TO RESEARCH WHICH

Urolithin A for mitochondrial-quality endpoints; NMN for NAD+-metabolism endpoints. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Urolithin A] Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults — Cell Rep Med 2022. PMID 35584623
[Urolithin A] Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial — JAMA Netw Open 2022. PMID 35050355
[Urolithin A] Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial — Nat Aging 2025. PMID 41174221
[NMN] Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women — Science 2021. PMID 33888596
[NMN] The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial — Geroscience 2023. PMID 36482258
[NMN] Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study — Geroscience 2024. PMID 38789831

FREQUENTLY ASKED

What is the difference between Urolithin A and NMN?

Both target mitochondrial ageing from different angles: urolithin A promotes removal of damaged mitochondria, while NMN replenishes NAD+, a coenzyme mitochondria need.

What is the regulatory status of Urolithin A and NMN?

Urolithin A: Several randomised human trials in middle-aged and older adults and athletes; marketed as a supplement. NMN: Multiple small randomised human trials (insulin sensitivity, walking speed, aerobic capacity, sleep). Regulatory status of NMN as a supplement varies by country.

What safety signals have been reported?

Urolithin A: Trials report it as well tolerated over the study periods. NMN: Trials and reviews report it as well tolerated over weeks to months; long-term human data are still limited.

Which studies is this comparison based on?

For Urolithin A: “Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults” (PMID 35584623); “Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial” (PMID 35050355); “Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial” (PMID 41174221). For NMN: “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women” (PMID 33888596); “The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial” (PMID 36482258); “Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study” (PMID 38789831).